Overview Dividends

(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47

Xywav, Xyrem, Epidiolex, Rylaze, Vyxeos

EPS (Earnings per Share)

EPS (Earnings per Share) of JAZZ over the last years for every Quarter: "2020-09": 4.31, "2020-12": 4, "2021-03": 3.92, "2021-06": 3.9, "2021-09": 4.2, "2021-12": 4.21, "2022-03": 3.73, "2022-06": 4.3, "2022-09": 5.17, "2022-12": -0.07, "2023-03": 3.95, "2023-06": 4.51, "2023-09": 4.84, "2023-12": 5.02, "2024-03": 2.68, "2024-06": 5.3, "2024-09": 6.61, "2024-12": 6.6, "2025-03": -1.52, "2025-06": -8.25, "2025-09": 8.13,
EPS Growth (3y CAGR): 27.38%
EPS Trend (3y Corr): -23.6%
Last SUE: 0.91σ
Qual. Beats: 1

Revenue

Revenue of JAZZ over the last years for every Quarter: 2020-09: 600.888, 2020-12: 665.517, 2021-03: 607.581, 2021-06: 751.811, 2021-09: 838.115, 2021-12: 896.731, 2022-03: 813.721, 2022-06: 932.878, 2022-09: 940.652, 2022-12: 972.123, 2023-03: 892.812, 2023-06: 957.317, 2023-09: 972.14, 2023-12: 1011.935, 2024-03: 901.983, 2024-06: 1023.825, 2024-09: 1054.969, 2024-12: 1088.173, 2025-03: 897.841, 2025-06: 1045.712, 2025-09: 1126.107,
Revenue Growth (3y CAGR): 5.49%
Revenue Trend (3y Corr): 56.0%
Last SUE: 0.49σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 32.2%
Value at Risk 5%th 48.5%
Relative Tail Risk -8.50%
Reward TTM
Sharpe Ratio 1.13
Alpha 39.30
Character TTM
Hurst Exponent 0.617
Beta 0.735
Beta Downside 1.115
Drawdowns 3y
Max DD 39.07%
Mean DD 21.84%
Median DD 22.94%

Description: JAZZ Jazz Pharmaceuticals November 06, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a Dublin-based specialty biopharma that develops and commercializes products across neurology, oncology, and hematology in the U.S., Europe, and other markets. Its approved portfolio includes Xywav and Xyrem for narcolepsy-related sleep disorders, Epidiolex for rare epilepsies, Rylaze/Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma, Zepzelca for small-cell lung cancer, Ziihera for HER-2 positive biliary tract cancers, Defitelio for veno-occlusive disease, and Vyxeos for therapy-related acute myeloid leukemia. The pipeline features late-stage assets such as Zanidatamab (Phase 3 HER-2 GEA), Suvecaltamide (Phase 2 Parkinson’s tremor), and several early-stage candidates targeting RAF kinase, interferon-alpha, and sleep disorders.

Key quantitative points (FY 2023): revenue of approximately $2.5 billion, with >55 % derived from specialty CNS and oncology products; R&D intensity around 15 % of sales, reflecting a focus on high-margin, niche indications; and a cash-and-equivalents position of roughly $1.2 billion, providing runway for upcoming trial readouts. Macro-level drivers include an aging population that expands demand for sleep-disorder therapies, continued growth in the global oncology market (projected CAGR ≈ 6 % through 2030), and favorable reimbursement trends for specialty drugs in the U.S.

For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of Jazz’s valuation metrics and scenario analysis.

JAZZ Stock Overview

Market Cap in USD 8,611m
Sub-Industry Pharmaceuticals
IPO / Inception 2007-06-01
Return 12m vs S&P 500 31.8%
Analyst Rating 4.44 of 5

JAZZ Dividends

Currently no dividends paid

JAZZ Growth Ratios

Metric Value
CAGR 3y 4.77%
CAGR/Max DD Calmar Ratio 0.12
CAGR/Mean DD Pain Ratio 0.22
Current Volume 1664.5k
Average Volume 961.3k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-368.5m TTM) > 0 and > 6% of Revenue (6% = 249.5m TTM)
FCFTA 0.12 (>2.0%) and ΔFCFTA 2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 35.64% (prev 84.16%; Δ -48.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.12 (>3.0%) and CFO 1.39b > Net Income -368.5m (YES >=105%, WARN >=100%)
Net Debt (4.19b) to EBITDA (257.5m) ratio: 16.28 <= 3.0 (WARN <= 3.5)
Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (61.6m) change vs 12m ago -2.48% (target <= -2.0% for YES)
Gross Margin 85.39% (prev 85.58%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 35.22% (prev 32.58%; Δ 2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.13 (EBITDA TTM 257.5m / Interest Expense TTM 200.9m) >= 6 (WARN >= 3)

Altman Z'' 0.72

(A) 0.13 = (Total Current Assets 3.76b - Total Current Liabilities 2.27b) / Total Assets 11.36b
(B) 0.04 = Retained Earnings (Balance) 442.7m / Total Assets 11.36b
(C) -0.04 = EBIT TTM -428.0m / Avg Total Assets 11.81b
(D) -0.02 = Book Value of Equity -126.6m / Total Liabilities 7.40b
Total Rating: 0.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 50.61

1. Piotroski 5.0pt
2. FCF Yield 11.14%
3. FCF Margin 32.14%
4. Debt/Equity 1.37
5. Debt/Ebitda 16.28
6. ROIC - WACC (= -11.43)%
7. RoE -9.25%
8. Rev. Trend 55.97%
9. EPS Trend -23.57%

What is the price of JAZZ shares?

As of November 22, 2025, the stock is trading at USD 175.74 with a total of 1,664,510 shares traded.
Over the past week, the price has changed by +24.01%, over one month by +30.32%, over three months by +47.59% and over the past year by +47.38%.

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.
  • Strong Buy: 10
  • Buy: 6
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the JAZZ price?

Issuer Target Up/Down from current
Wallstreet Target Price 188.9 7.5%
Analysts Target Price 188.9 7.5%
ValueRay Target Price 193.4 10%

JAZZ Fundamental Data Overview November 15, 2025

Market Cap USD = 8.61b (8.61b USD * 1.0 USD.USD)
P/E Forward = 6.9735
P/S = 2.071
P/B = 2.0977
P/EG = 6.1166
Beta = 0.332
Revenue TTM = 4.16b USD
EBIT TTM = -428.0m USD
EBITDA TTM = 257.5m USD
Long Term Debt = 4.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.19b USD (from netDebt column, last quarter)
Enterprise Value = 11.99b USD (8.61b + Debt 5.43b - CCE 2.05b)
Interest Coverage Ratio = -2.13 (Ebit TTM -428.0m / Interest Expense TTM 200.9m)
FCF Yield = 11.14% (FCF TTM 1.34b / Enterprise Value 11.99b)
FCF Margin = 32.14% (FCF TTM 1.34b / Revenue TTM 4.16b)
Net Margin = -8.86% (Net Income TTM -368.5m / Revenue TTM 4.16b)
Gross Margin = 85.39% ((Revenue TTM 4.16b - Cost of Revenue TTM 607.4m) / Revenue TTM)
Gross Margin QoQ = 77.11% (prev 88.88%)
Tobins Q-Ratio = 1.06 (Enterprise Value 11.99b / Total Assets 11.36b)
Interest Expense / Debt = 0.89% (Interest Expense 48.6m / Debt 5.43b)
Taxrate = -2683 % (out of range, set to none) (-242.4m / 9.04m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.65 (Total Current Assets 3.76b / Total Current Liabilities 2.27b)
Debt / Equity = 1.37 (Debt 5.43b / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = 16.28 (Net Debt 4.19b / EBITDA 257.5m)
Debt / FCF = 3.14 (Net Debt 4.19b / FCF TTM 1.34b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.24% (Net Income -368.5m / Total Assets 11.36b)
RoE = -9.25% (Net Income TTM -368.5m / Total Stockholder Equity 3.98b)
RoCE = -5.15% (EBIT -428.0m / Capital Employed (Equity 3.98b + L.T.Debt 4.33b))
RoIC = -6.08% (negative operating profit) (EBIT -428.0m / (Assets 11.36b - Curr.Liab 2.27b - Cash 2.05b))
WACC = 5.35% (E(8.61b)/V(14.04b) * Re(8.72%) + (debt cost/tax rate unavailable))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.97%
[DCF Debug] Terminal Value 78.89% ; FCFE base≈1.25b ; Y1≈1.51b ; Y5≈2.42b
Fair Price DCF = 599.1 (DCF Value 36.40b / Shares Outstanding 60.8m; 5y FCF grow 21.58% → 3.0% )
EPS Correlation: -23.57 | EPS CAGR: 27.38% | SUE: 0.91 | # QB: 1
Revenue Correlation: 55.97 | Revenue CAGR: 5.49% | SUE: 0.49 | # QB: 0

Additional Sources for JAZZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle